Status:
COMPLETED
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Lead Sponsor:
Palo Alto Veterans Institute for Research
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Hemodialysis
Kidney Failure, Chronic
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
Detailed Description
Hemodialysis patients who have residual kidney function will undergo two 4-week study (twice weekly versus thrice weekly hemodialysis) using a cross-over design. Blood, urine, and dialysate samples wi...
Eligibility Criteria
Inclusion
- patients on hemodialysis who have residual kidney function with residual urea clearance (Kru) \>2.5 mL/min.
- been on hemodialysis for at least 3 months.
- adherence to regular dialysis treatments.
Exclusion
- inability to achieve adequate hemodialysis.
- planned revision of hemodialysis vascular access.
- hospitalized within the past 2 months.
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT03874117
Start Date
July 1 2018
End Date
May 31 2025
Last Update
September 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
2
Santa Clara Valley Medical Center
San Jose, California, United States, 95128
3
Satellite HealthCare
San Jose, California, United States, 95128